Francais
info@saveyourskin.ca

immunotherapy

ASCO 2020 Event Report

In 2020, the American Society of Clinical Oncology meeting was held online due to the COVID-19 pandemic. The meeting took place from May 29th-31st, with the last two days being devoted to online presentations.

This report will be dedicated to the presentations that representatives from Save Your Skin Foundation remotely attended, with a focus on melanoma, innovative treatments, and survivorship. The information in this report is sourced directly, occasionally verbatim, from ASCO presentations and abstracts. If you require more information on an abstract, the clinical trial numbers (where available) are included for your reference.

Please CLICK HERE to read or download the report.

 

Feedback or questions?  Contact us – info@saveyourskin.ca

Read more

SYSF Webinar – Melanoma Treatment FAQs: Do’s, Don’ts, and How to Manage Side Effects

 

Recording available! 

Join us to hear the latest updates on current immunotherapy and targeted therapy treatments for melanoma and non-melanoma skin cancers in Canada. 

Dr. Smylie and Dr. Iafolla will hold a panel discussion on recommended dietary and lifestyle habits while on treatment, as well as managing toxicities from fever and pneumonitis to dermatologic complications from immune checkpoint inhibitors.

Presenters:

  • Dr. Michael Smylie, Medical Oncologist, Cross Cancer Institute, Professor, Department of Oncology, University of Alberta, Edmonton
  • Dr. Marco Iafolla, MD, MSc, FRCPC, Assistant Professor, University of Toronto, Medical Oncologist, Genitourinary and Cutaneous Site Lead, William Osler HS

Click HERE to view the recording!

 

Read more

ASCO 2019 Event Report

The 2019 American Society of Clinical Oncology Annual Meeting took place from May 31-June 4, 2019 in Chicago, Illinois. This event brings together over thirty thousand oncologists, pharmaceutical representatives, and patient advocates from across the world and across cancer types for five days of networking, learning, and presenting new research.

Every year, Save Your Skin Foundation puts together a report of the panels regarding updates on the innovative treatment of melanoma, non-melanoma skin cancer, and ocular melanoma. Included in the report are detailed recollections of these panels, in chronological order.

Please CLICK HERE to download and read the report.

 

Feedback or questions?  Contact us – info@saveyourskin.ca

Read more

PeerVoice – Advances in Adjuvant Melanoma Therapy

We are pleased to announce that the PeerVoice activity entitled ”Advances in Adjuvant Melanoma Therapy: Working Together To Improve Outcomes’’ has now launched online.  SYSF is proud to endorse this work, and applauds the valuable work put into this educational resource.

This initiative features two expert panel discussions, verbally presented by:

Michael Smylie, MBCHB, FRCPC, Edmonton, Alberta

Joël Claveau, MD, FRCPC, Quebec City, Quebec

Carolyn Nessim, MD, MSc, FRCSC, FACS, Ottawa, Ontario

Presentation 1: Adjuvant Melanoma Therapy: Optimizing the Care Pathway

Presentation 2: Adjuvant Melanoma Therapy: Experts Appraise the Evidence

These verbal interview-style presentations are also available as downloadable transcripts, click here to view or read the presentations: PeerVoice: Advances in Adjuvant Melanoma Therapy

PeerVoice activities are designed to fill the unmet needs of the medical community by reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine.  This independent learning activity is supported by Merck Canada Inc.

 

NEW! December 2019:  Minding the Melanoma Patient With Brain Metastases: Updates to Personalize Care

Listen to the recording, and/or download the presentation, by:
Marcus Butler, Medical Oncologist, University of Toronto  |  Princess Margaret Cancer Centre

Raising the Bar With Immunotherapy for Melanoma and Kidney Cancer: Strategies to Enhance Care. This independent learning activity is funded by Bristol-Myers Squibb Canada Co.

Read more

Introducing Think Uveal Melanoma, by Immunocore

We are happy to share with you the launch of chapter 1 of a new Uveal Melanoma Disease Education Campaign website by Immunocore, thinkuvealmelanoma.com. (Note: Please use Google Chrome for the best user experience). We are pleased to endorse this website and to share it with our Medical Advisory Board and membership.

This initiative is an important milestone in educating and increasing the knowledge of ocular and uveal melanoma (UM) and its unique requirements, for healthcare professionals. This includes increasing the knowledge surrounding the diagnosis, referral, monitoring and treatment of UM, across the full spectrum of key stakeholders, such as Ophthalmologists, Ocular Oncologists, Retina Specialists, Medical Oncologists, in both community and academic centers.

This global campaign consists of three chapters that will be launched over the course of this year. Chapters 2 and 3 will educate healthcare professionals about the differences between uveal and cutaneous melanoma and the limitations of current treatment options. Global experts in the field of UM are partnering with Immunocore to create meaningful and relevant content. A multi-channel engagement campaign is surrounding the website to reach a broad range of key stakeholders and allowing for multiple virtual touchpoints.

Ultimately, Immunocore wants to

  • raise awareness of the unmet need in UM
  • educate physicians and other key stakeholders on metastatic UM (mUM) and the differences to metastatic cutaneous melanoma (mCM)
  • convey their commitment to exploring ways to address the distinct unmet needs of patients with UM

 

Click here to view the website, background information, and even an interactive module which simulates possible symptoms of UM: thinkuvealmelanoma.com

Read more

SYSF Webinar: Ocular Melanoma

Ocular Melanoma – Innovative Treatments and Beyond

With Presenters:

Dr. Marcus Butler, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Dr. Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, California

Nigel Deacon, Ocular Melanoma Survivor/Patient, British Columbia, Canada

This webinar provides an update on the landscape of metastatic ocular melanoma treatment in Canada and the United States. Dr. Hamid and Dr. Butler share their knowledge of current practices and care pathways, identifying the most pressing needs for patients. They also discuss innovative treatment options such as IMCgp100, as well as clinical trials available to Canadian patients with ocular or uveal melanoma. Nigel Deacon shares his experience with this rare cancer; Kathy Barnard facilitating.

Missed the webinar? Listen to a recording of the presentation here, or watch it on our YouTube channel here.

Read more

Introducing “ForPatients” by Roche

We are happy to announce the launch of an informative website about clinical trials by another of our supporting partners.  F. Hoffmann-La Roche Ltd. has put together a website called ForPatients, which includes a search tool for finding clinical trials in various cancer indications, plus other medical conditions such as autoimmune or neurodegenerative disorders.  Anyone can search for clinical trials around the world; it is easy to navigate, and even includes an interactive map showing recruiting clinical trial locations.

ForPatients also contains detailed information about clinical trials in general, and discusses patients’ rights in and after a clinical trial. It also points out where to find published results of any given Roche trials, and it has general care tips for patients plus links to additional support resources.

We applaud Roche for this initiative, and wish patients around the world much success with this valuable new resource.  Click here to check out the new website:

ForPatients.Roche.com

 

Read more

SYSF Webinar: Treatment Options for Melanoma Patients in the Adjuvant Setting

Join us for this free webinar, which reviews the latest news and clinical data related to melanoma treatment in the adjuvant setting, as presented in the 2018 conference season.

‘Adjuvant’ refers to patients with a stage II or stage III diagnosis. The majority of adjuvant patients typically undergo surgery to have their tumour(s) removed, but are not given immunotherapy or targeted therapy to prevent recurrence of the disease despite a known high-risk of relapse and mortality. Melanoma is an aggressive cancer; stage III melanoma means the cancer has spread from skin cells into the lymphatic system, and poses a dangerous risk for spread to organs, which is what depicts a stage IV diagnosis.

Dr. Claveau shares his key insights into what the landscape of adjuvant melanoma immuno-oncology treatment looks like for the near future in Canada. Dr. Adrian Gunaratne details the science behind targeted therapy and what is coming for Canadian melanoma patients in the adjuvant setting with a BRAF positive mutation. The discussion continues with a patient and a caregiver both having had treatment access challenges in the adjuvant melanoma setting, and how their experiences impacted their lives and that of their families.

Presenters:

  • Dr. Joel Claveau, Medical Oncologist, Hotel-Dieu de Quebec, Université Laval, Quebec City, QC
  • Adrian Gunaratne, PhD, Medical Science Liaison – Solid Tumors, Novartis Pharmaceuticals Canada
  • Natalie Richardson, Adjuvant Melanoma Patient, Managing Director, Save Your Skin Foundation
  • Eyyub Hajiyev, Caregiver to a loved one recently diagnosed with melanoma in the adjuvant setting

Read more

National Post: Therapeutic Spotlight on Immuno-Oncology

On September 26, 2018, you may have seen a special insert in the paper version of the National Post across the country, featuring eight pages of informative articles about immunotherapy, an innovative treatment proving successful in several cancer indications.  This special content is the result of a collaboration between sponsoring funders, patient group representatives, and the folks at a group called Patient Diaries.  Over the years, Patient Diaries has coordinated several series such as this, raising awareness of various diseases and their effective treatments.                                                        This time they chose to highlight Immuno-Oncology.

Researchers and clinicians treating metastatic melanoma have been seeing success with these therapies for about ten years, but the growing use of and experimentation with them in recent years has been the topic of discussion at countless oncology conferences and treatment centres around the world.  In fact, just last month the 2018 Nobel Prize in Physiology or Medicine was awarded to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation: immunotherapy.

Save Your Skin Foundation openly discusses the need for access to these treatments by melanoma patients across Canada, and we jumped on the opportunity to be the primary patient group sponsor of this feature, sharing our collective patient experience with these therapies. On page six of the insert there was an article in which both Kathy Barnard and Natalie Richardson of Save Your Skin were interviewed.  We were also given half a page to display informative anecdotes about ourselves and raise awareness of our ongoing support of skin cancer patients.

In addition to the paper version of the Therapeutic Spotlight, a digital space has been placed on the National Post website.  SYSF awareness spots and our patient video from May 2018 can be seen throughout the Immuno-Oncology board – please feel free to take a look around.  There are additional informative articles about innovative treatments for lung cancer, leukemia, and breast cancer.

There is also a blog written by Natalie Richardson, melanoma survivor and Managing Director of SYSF, discussing the barriers to treatment access that many Canadian patients face.  Click here to read the blog: Cancer Patients Receive Unequal Treatment Depending on Stage or Postal Code

To see what else SYSF is talking about, click here to visit our MEDIA page!

Read more

Adjuvant Patient Survey: here is the full report!

In September 2018, Save Your Skin Foundation (SYSF) conducted an anonymous survey of melanoma patients in the adjuvant setting (diagnosed at a stage lesser than stage IV).  This survey, titled “Melanoma Treatments in the Adjuvant Setting,” was open globally, and we received responses from all over Canada as well as from the United States, New Zealand, and Australia.

The survey consisted of 28 questions, which ranged between multiple choice, multi-selection, and write-in, and participants had the option to skip any question. The goal of the survey was to assess the impact melanoma has on patients and their families and caregivers, and get a picture of the treatment plan of the average melanoma patient, what treatment access limitations they have encountered, and what they look for in potential treatment options.

The responses to this survey were used to inform SYSF submissions to provide direct patient feedback as treatment recommendations to pCODR and INESSS.  We provided these submissions with all of the patient comments to support the message that melanoma patients in the adjuvant setting need access to immuno-oncology treatments to prevent their disease from growing into a stage IV diagnosis.

Thank you to all participants who took the time and care to share their perspectives.  We have every hope that the drugs in the pipeline for adjuvant will be approved in every province and territory in Canada.

To read the full Survey Report, please click HERE To request any additional information about the survey please feel free to email info@saveyourskin.ca

 

Read more